Molecular targeted therapy of non-small cell lung cancer / 国际肿瘤学杂志

ABSTRACT

At present,the treatment of non-small cell lung cancer (NSCLC) has entered the era of targeted therapy,and small molecule tyrosine kinase inhibitors are typical representatives,which have clear molecular targets and remarkable effects.But many patients without mutations are not able to benefit from them.Vascular endothelial growth factor and immune targeted therapy have become the new focus of NSCLC treatment.Inhibitors such as programmed cell death-1 and programmed cell death-ligand 1 have shown great applied potential in a series of clinical trials of NSCLC.